Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$2.64 -37.9%	$1.36	$0.46 ▼ $7.49	$22.72M	-0.1	19.99 million shs	13.26 million shs
MIRA MIRA Pharmaceuticals	$1.43 +2.1%	$1.44	$0.73 ▼ $2.70	$26.70M	1.77	324,219 shs	171,033 shs
PHGE BiomX	$0.54 -26.9%	$0.46	$0.34 ▼ $2.40	$14.54M	1.42	347,190 shs	53,300 shs
TENX Tenax Therapeutics	$6.00 -0.7%	$5.94	$3.25 ▼ $7.89	$27.56M	1.46	21,375 shs	7,744 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	-37.88%	+89.93%	+36.79%	+197.33%	-14.84%
MIRA MIRA Pharmaceuticals	+2.14%	-4.67%	-20.56%	+17.21%	-27.78%
PHGE BiomX	-1.46%	-2.70%	+21.08%	+5.26%	-63.29%
TENX Tenax Therapeutics	-0.66%	+0.50%	-0.08%	-0.83%	+42.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APM Aptorum Group	0.7511 of 5 stars	0.0	2.0	3.9	1.7	0.0
MIRA MIRA Pharmaceuticals	3.0577 of 5 stars	3.8	5.0	2.2	0.0	0.6
PHGE BiomX	2.1155 of 5 stars	3.5	0.0	1.1	0.8	1.3
TENX Tenax Therapeutics	1.6686 of 5 stars	3.6	1.0	1.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APM Aptorum Group	0.00	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	3.50	Strong Buy	$17.00	1,088.81% Upside
PHGE BiomX	3.00	Buy	$21.00	3,788.89% Upside
TENX Tenax Therapeutics	3.25	Buy	$17.00	183.33% Upside

Current Analyst Ratings Breakdown

Latest APM, PHGE, MIRA, and TENX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/14/2025	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APM Aptorum Group	N/A	N/A	N/A	N/A	$2.20 per share	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.03 per share	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	$0.70 per share	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	$22.65 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APM Aptorum Group	-$4.27M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	-$7.85M	-$0.49	N/A	N/A	N/A	N/A	-406.70%	-328.44%	11/11/2025 (Estimated)
PHGE BiomX	-$28.32M	-$1.36	N/A	N/A	N/A	N/A	-127.82%	-56.50%	N/A
TENX Tenax Therapeutics	-$17.60M	-$0.92	N/A	N/A	N/A	N/A	-31.34%	-30.39%	N/A

Latest APM, PHGE, MIRA, and TENX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	MIRA MIRA Pharmaceuticals	-$0.11	-$0.09	+$0.02	-$0.09	N/A	N/A
8/13/2025	Q2 2025	TENX Tenax Therapeutics	-$0.50	-$0.27	+$0.23	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APM Aptorum Group	N/A	0.22	0.22
MIRA MIRA Pharmaceuticals	N/A	2.80	12.86
PHGE BiomX	0.51	2.84	2.84
TENX Tenax Therapeutics	N/A	41.89	41.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APM Aptorum Group	3.80%
MIRA MIRA Pharmaceuticals	35.16%
PHGE BiomX	40.57%
TENX Tenax Therapeutics	1.67%

Insider Ownership

Company	Insider Ownership
APM Aptorum Group	63.99%
MIRA MIRA Pharmaceuticals	6.65%
PHGE BiomX	1.17%
TENX Tenax Therapeutics	3.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APM Aptorum Group	30	5.35 million	1.93 million	Not Optionable
MIRA MIRA Pharmaceuticals	2	19.07 million	17.80 million	Not Optionable
PHGE BiomX	120	26.53 million	44.04 million	Not Optionable
TENX Tenax Therapeutics	9	4.56 million	4.42 million	Not Optionable

APM, PHGE, MIRA, and TENX Headlines

Recent News About These Companies

Leerink Partnrs Has Negative Forecast for TENX Q3 Earnings

August 19, 2025 | americanbankingnews.com

William Blair Brokers Decrease Earnings Estimates for TENX

August 19, 2025 | americanbankingnews.com

Q3 EPS Estimate for Tenax Therapeutics Reduced by Analyst

August 18, 2025 | americanbankingnews.com

Equities Analysts Set Expectations for TENX FY2028 Earnings

August 17, 2025 | americanbankingnews.com

Tenax Posts Wider Loss in Fiscal Q2

August 14, 2025 | aol.comA

Tenax Therapeutics reports Q2 EPS (27c), consensus (45c)

August 14, 2025 | msn.com

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | globenewswire.com

TENX Tenax Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | globenewswire.com

Tenax Therapeutics Inc.

May 9, 2025 | barrons.com

Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts

April 16, 2025 | seekingalpha.com

Tenax Therapeutics files to sell 4.14M shares of common stock for holders

April 16, 2025 | markets.businessinsider.com

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025 | globenewswire.com

Tenax Therapeutics reports Q4 EPS (18c), consensus (43c)

March 27, 2025 | markets.businessinsider.com

Tenax Therapeutics (TENX) Gets a Buy from William Blair

March 27, 2025 | markets.businessinsider.com

Tenax Therapeutics: Q4 Earnings Snapshot

March 25, 2025 | timesunion.comT

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 25, 2025 | globenewswire.com

Tenax Therapeutics Inc TENX

March 14, 2025 | morningstar.comM

Roth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)

March 6, 2025 | markets.businessinsider.com

Tenax Therapeutics expands Phase 3 LEVEL program for TNX-103

March 5, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

APM, PHGE, MIRA, and TENX Company Descriptions

Aptorum Group NASDAQ:APM

$2.64 -1.61 (-37.88%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.54 -0.10 (-3.64%)

As of 08/22/2025 08:00 PM Eastern

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

MIRA Pharmaceuticals NASDAQ:MIRA

$1.43 +0.03 (+2.14%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.44 +0.01 (+0.35%)

As of 08/22/2025 05:47 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

BiomX NYSEMKT:PHGE

$0.54 -0.20 (-26.93%)

Closing price 08/22/2025 03:57 PM Eastern

Extended Trading

$0.54 +0.00 (+0.56%)

As of 08/22/2025 08:00 PM Eastern

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Tenax Therapeutics NASDAQ:TENX

$6.00 -0.04 (-0.66%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.86 -0.14 (-2.25%)

As of 08/22/2025 06:57 PM Eastern

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time